News
Novo Nordisk is partnering with the biotech Septerna to develop oral obesity drugs, as it aims for more convenient weight ...
Meanwhile, Eli Lilly's Zepbound injection has gained traction, prompting both firms to race toward more convenient ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback